Top 10 Cardiology Articles of the week (24.11.14 – 30.11.14) 1. Transcatheter Closure of Large Atrial Septal Defects: Feasibility and Safety in a Large Adult and Pediatric Population Conclusions—Closure of large atrial septal defects using the Amplatzer device is safe and effective in both adults and children. Superior and posterior rim deficiencies are associated with […]
Top 10 Cardiology articles of the week (10.11.14-16.11.14) Hello friends , I have been busy for sometime. Now journal scan is back again after a brief interruption. I have chosen articles on general cardiology and interventional cardiology 1. The optimal management of anti-thrombotic therapy after valve replacement: […]
A new class of drug (Neprilysin inhibitor ) when combined with angiotensin receptor blocker , has been shown to be better than Enalapril. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure — NEJM.
HPS2-THRIVE trial Among patients with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients — NEJM.
STENTYS SELF APPOSITION SES: It is a self-expandable sirolimus-eluting coronary stent system, similar in concept to other self-expanding systems. Watch the video: Stentys self-apposition SES APPOSITION IV trial: –Patients – 152 patients presenting with STEMI. –Design: Patients were randomized to Stentys self-apposing SES (Stentys, Paris, France; n = 90) vs Resolute zotarolimus-eluting stent (ZES; Medtronic, […]
CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device – EuroPCR 2014 – TCTMD.
Background—The optimal long-term antithrombotic treatment of patients with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and commonly, a single antiplatelet agent is added to oral anticoagulation. The study investigated the effectiveness and safety of adding antiplatelet therapy to vitamin K antagonist (VKA) in atrial fibrillation patients with stable coronary artery disease. Methods […]
This article in JACC examines the rates of MI in patients with ACS treated with ticagrelor vs clopidogrel. The rates of overall MI at 12 months: 1. Ticagrelor- 5.8% 2. Clopidogrel – 6.9% 3. Nonprocedural MI (HR: 0.86; 95% CI: 0.74 to 1.01) and MI related to percutaneous coronary intervention or stent thrombosis tended […]